Ivabradine reduces total hospital burden in heart failure

摘要

Heart rale reduction using ivabradine in patients with chronic heart failure who were in sinus rhythm and with heart rates of at least 70 beats/min resulted in substantially reduced clinical deterioration in total hospitalisations for worsening heart failure and in an increase in time to first and subsequent hospitalisations. This was despite patients being treated with guideline-based background therapy, including maximally treated beta-blockade. Presenting the results of the post-hoc analysis of the SHIT study, which focused on recurrent hospitalisation, Prof Jeffrey Borer, New York, stressed that ivabradine therapy did not unmask any other problems that would lead to hospitalisation. 'In the Total Time Analysis, the time to occurrence of hospitalisation for heart failure was reduced for first events by 25%, for second events by 34%, and for a third event by 29%. All of these reductions were highly statistically significant', Prof Borer pointed out.